Table 1.
References | Region | Study setting | Study design | Sample size | Cause | Prevalence | quality |
---|---|---|---|---|---|---|---|
Dagnew et al. (26) | Amhara | Institutional | cross-sectional | 527 | NR | 37 | Low-risk |
Nageso and Gebretsadik (27) | SNNPR | Community | Cross-sectional | 683 | Side effect | 23.4 | Low- risk |
Siyoum et al. (27) | Amhara | Community | Cross-sectional | 314 | Menstrual problem | 40.5 | Low- risk |
Wondie et al. (29) | Amhara | Community | Cross-sectional | 312 | Side effect | 16.7 | Low -risk |
Melkamu et al. (30) | Amhara | Institutional | Cross-sectional | 499 | Side effect | 65 | Low-risk |
Weldekidan et al. (31) | SNNPR | Community | Cross-sectional | 222 | Menstrual problem | 22.5 | Low-risk |
Gaenamo (32) | SNNPR | Institutional | Cohort | 473 | Desire of pregnancy | 38.4 | Low-risk |
Abebe et al. (23) | SNNPR | Institutional | Cross-sectional | 442 | Menstrual problem | 56.6 | Low-risk |
Obsu et al. (33) | Oromia | Commuity | Cross-sectional | 360 | Side effect | 42 | Low-risk |
Mesha et al. (34) | SNNPR | Community | Cross-sectional | 430 | NR | 34 | Low-risk |
Habte et al. (35) | SNNPR | Institutional | Cohort | 502 | Side effect | 40.5 | Low-risk |
Amare and Reda (36) | SNNPR | institutional | Cross-sectional | 351 | Menstrual problem | 49.3 | Low-risk |
Nega et al. (37) | SNNPR | Community | Cross-sectional | 475 | Side effect | 23.2 | Low-risk |
Tesfaye et al. (38) | Oromia | Community | Cross-sectional | 430 | NR | 19.3 | Low-risk |
Geja et al. (39) | SNNPR | Community | Cross-sectional | 429 | Desire of pregnancy | 22.4 | Low-risk |
Tolesa et al. (44) | SNNPR | Institution | Cross-sectional | 1,050 | Side effect | 69.8 | Low-risk |
Abraha et al. (40) | Tigray | Institutional | Cohort | 413 | Side effect | 18.2 | Low –risk |
Gebrekidan et al. (42) | Tigray | Institutional | Cross-sectional | 229 | Desire of pregnancy | 38 | Low-risk |
Birhane (43) | Tigray | Community | Cross-sectional | 224 | Health concern | 16 | Low-risk |
Yilkal (41) | Amhara | Institutional | Cross-sectional | 415 | Side effect | 66 | Low-risk |